title: Therapeutic potential of fucoidan in myocardial ischemia.
abstract: Fucoidan, a sulfated polysaccharide extracted from brown seaweed, is a candidate for the treatment of ischemic diseases. The aim of this study was to measure the therapeutic potential of fucoidan in a rat model of myocardial ischemia-reperfusion injury. Forty rats were submitted to myocardial ischemia-reperfusion injury by transient occlusion of the left coronary artery. Rats were then randomized into 2 groups: fucoidan (5 mg/kg, intramuscularly; n = 20) or control (saline intramuscularly; n = 20) was administered 1 hour before injury and daily thereafter for 1 month. At 1 month, plasma levels of stromal cell-derived factor-1α (SDF-1α) were assessed by enzyme-linked immunosorbent assay kit. Hearts were evaluated by histoimmunochemistry. Fucoidan induced significant antifibrotic effects, reducing the infarct scar size by almost 30% on Sirius red-stained sections (9.45% ± 4.27% vs. 13% ± 5.67% in controls; P = 0.03). Vascular density in the fucoidan group (α-actin, RECA-1, or lectin BS1 stained) was increased by 40% (2.18 ± 0.79 mm vs. 1.49 ± 0.42 mm in controls ×200; P = 0.001). Plasma SDF-1α at 1 month was not significantly different between the 2 groups. However, increased immunostaining density of SDF-1α and vascular endothelial growth factor in fibrotic ischemic tissues was observed in fucoidan-treated animals versus controls. In conclusion, fucoidan enhanced tissue repair in myocardial ischemia-reperfusion by promoting revascularization (in situ vascular endothelial growth factor and SDF-1α overexpression) and limiting fibrosis. Consequently, fucoidan may be useful for myocardial ischemic patients.
authors.affiliation: Inserm, U 698, Cardiovascular Remodelling, CHU Xavier Bichat-Claude Bernard, University of Paris Diderot, Paris, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Manzo-Silberman
authors.forename: Liliane
authors.initials: L
authors.lastname: Louedec
authors.forename: Olivier
authors.initials: O
authors.lastname: Meilhac
authors.forename: Didier
authors.initials: D
authors.lastname: Letourneur
authors.forename: Jean-Baptiste
authors.initials: JB
authors.lastname: Michel
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Elmadbouh
mesh_terms: D000818:Animals; D054377:Chemokine CXCL12 / Q000378:metabolism; D003331:Coronary Vessels / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005355:Fibrosis; D007273:Injections, Intramuscular; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000503:physiopathology; D009204:Myocardial Revascularization / Q000379:methods; D011134:Polysaccharides / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D011917:Rats, Inbred Lew; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D054377:Chemokine CXCL12; D011134:Polysaccharides; D042461:Vascular Endothelial Growth Factor A; C007789:fucoidan